Tango Therapeutics, Inc. (TNGX) · Oct 23, 2026 · Other events
Phase 3 planned — 82% ORR in 22 PDAC patients; Phase 3 targeted for 1H27
Tango Therapeutics’ clinical data preserve a strong PDAC signal and support a Phase 3 path, but a 14% workforce reduction narrows the pipeline.
Tango is shifting from a research-led biotech toward a focused PRMT5 clinical developer, with vopimetostat plus RAS inhibition now the lead pancreatic-cancer program. The June 2026 dataset had already shown a 92% response rate and pointed toward Phase 3 development, so the direction of travel was known before this filing.
The pancreatic-cancer signal remains unusually strong, but the headline efficacy number is less impressive than in June. In the larger, longer-followed group, vopimetostat plus daraxonrasib produced an 82% response rate in 22 efficacy-evaluable second- or third-line PDAC patients, with median PFS not reached, an 88% nine-month PFS rate, and 100% disease control. 〔0〕 The 92% ORR from the initial June snapshot fell to 82% as the evaluable population expanded, which is a modest statistical step back, but all seven responses that were unconfirmed at the cutoff were subsequently confirmed. 〔1〕
The update materially advances the program toward a registrational test. Following FDA discussions, Tango now plans a global randomized trial in first-line MTAP-deleted PDAC, comparing the combination with standard chemotherapy, with ORR and PFS as dual primary endpoints. 〔2〕 That is more concrete than the prior plan to finalize a Phase 3 design in the second half of 2026, although the company still needs clinical supply of daraxonrasib and the trial remains a future execution event rather than validation of efficacy in first-line disease.
Safety supports the selected dose, but higher dosing remains a clear limitation. At dose level 1 in PDAC, there were no dose-limiting toxicities, no withdrawals for treatment-related adverse events, and no Grade 4 or 5 treatment-related adverse events; Grade 3 events affected 40% of patients. By contrast, dose level 2 was not well-tolerated, with three dose-limiting toxicities in two patients, reinforcing why the lower dose is being carried into the registrational study.
The strategic reprioritization improves focus but removes pipeline breadth. Tango is stopping some preclinical and novel-target work, including a planned second-line MTAP-wild-type PDAC combination study, and intends to cut its workforce by approximately 14%, mostly in research. 〔3〕 This concentrates resources behind vopimetostat and TNG456, but it also means the company is betting more heavily on a small number of clinical programs while reducing earlier-stage optionality.
Bottom line: The filing strengthens Tango’s lead PDAC program enough to establish a clearer Phase 3 path, but it is not an unqualified upgrade: the expanded dataset lowers the response rate from June’s headline and the company is narrowing its research base to fund execution around a concentrated pipeline.
Phase 3 PDAC trial initiation, first half 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!